BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 30316399)

  • 1. Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
    Ishiwatari A; Wakai S; Shirakawa H; Honda K
    Transplant Proc; 2018 Oct; 50(8):2565-2568. PubMed ID: 30316399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
    Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
    J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary membranous glomerulonephritis with negative serum PLA2R in haemophilia A successfully managed with rituximab - case report and review of the literature.
    Meyer N; Cooper W; Kirwan P; Garsia R; Dunkley S; Gracey DM
    BMC Nephrol; 2021 Jul; 22(1):268. PubMed ID: 34294065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phospholipase A2 receptor positive membranous nephropathy long after living donor kidney transplantation between identical twins.
    Saito H; Hamasaki Y; Tojo A; Shintani Y; Shimizu A; Nangaku M
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():101-4. PubMed ID: 26031599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
    Segarra-Medrano A; Jatem-Escalante E; Quiles-Pérez MT; Salcedo MT; Arbós-Via MA; Ostos H; Valtierra N; Carnicer-Cáceres C; Agraz-Pamplona I
    Nefrologia; 2014 May; 34(3):353-9. PubMed ID: 24798555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation.
    Gupta G; Fattah H; Ayalon R; Kidd J; Gehr T; Quintana LF; Kimball P; Sadruddin S; Massey HD; Kumar D; King AL; Beck LH
    Clin Transplant; 2016 Apr; 30(4):461-9. PubMed ID: 26854647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Beneficial Role Of Anti-Phospholipase A2 Receptor Auto-Antibodies And Rituximab In The Management Of Recurrent Primary Membranous Nephropathy After Kidney Transplantation.
    Anjum N; Nabi Z
    J Ayub Med Coll Abbottabad; 2021; 33(2):315-318. PubMed ID: 34137554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent membranous nephropathy in an allograft caused by IgG3κ targeting the PLA2 receptor.
    Debiec H; Hanoy M; Francois A; Guerrot D; Ferlicot S; Johanet C; Aucouturier P; Godin M; Ronco P
    J Am Soc Nephrol; 2012 Dec; 23(12):1949-54. PubMed ID: 23123401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Membranous nephropathy: New insights in therapeutic approach].
    Dahan K
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).
    Radice A; Trezzi B; Maggiore U; Pregnolato F; Stellato T; Napodano P; Rolla D; Pesce G; D'Amico M; Santoro D; Londrino F; Ravera F; Ortisi G; Sinico RA
    Autoimmun Rev; 2016 Feb; 15(2):146-54. PubMed ID: 26527329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.
    Brenchley PE
    J Am Soc Nephrol; 2015 Oct; 26(10):2308-11. PubMed ID: 25804283
    [No Abstract]   [Full Text] [Related]  

  • 12. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy.
    Hoxha E; Kneißler U; Stege G; Zahner G; Thiele I; Panzer U; Harendza S; Helmchen UM; Stahl RA
    Kidney Int; 2012 Oct; 82(7):797-804. PubMed ID: 22673885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
    Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
    BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregnancy in a Patient With Primary Membranous Nephropathy and Circulating Anti-PLA2R Antibodies: A Case Report.
    Al-Rabadi L; Ayalon R; Bonegio RG; Ballard JE; Fujii AM; Henderson JM; Salant DJ; Beck LH
    Am J Kidney Dis; 2016 May; 67(5):775-8. PubMed ID: 26744127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies.
    Bobart SA; De Vriese AS; Pawar AS; Zand L; Sethi S; Giesen C; Lieske JC; Fervenza FC
    Kidney Int; 2019 Feb; 95(2):429-438. PubMed ID: 30665573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy.
    Zhang L; Chen M; Le W; Zhang M; Tu Y; Zuo K; Chen D; Wu Y; Li S; Zeng C; Cheng Z; Xie H
    Immunotherapy; 2022 Oct; 14(15):1237-1244. PubMed ID: 36097696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A
    Tominaga K; Uchida T; Imakiire T; Itoh K; Shimazaki H; Nakanishi K; Kumagai H; Oshima N
    BMC Nephrol; 2018 May; 19(1):120. PubMed ID: 29792176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship of anti-phospholipase A2 receptor antibody and C5a complement with disease activity and short-term outcome in idiopathic membranous nephropathy.
    Chi JN; Lai TS; Wu CF; Fu TY; Chou YH; Chiu YL; Lin WC; Chiang WC; Chen YM; Wu MS
    J Formos Med Assoc; 2019 May; 118(5):898-906. PubMed ID: 30639075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membranous nephropathy with light chain restricted deposits.
    Ramachandran R; Inamdar N; Bharati J; Yadav AK; Kumar A; Prakash G; Nada R; Rathi M; Kohli HS; Gupta KL; Jha V
    Nephrology (Carlton); 2018 Aug; 23(8):791-796. PubMed ID: 29633425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous Nephropathy.
    Quintana LF; Blasco M; Seras M; Pérez NS; López-Hoyos M; Villarroel P; Rodrigo E; Viñas O; Ercilla G; Diekmann F; Gómez-Roman JJ; Fernandez-Fresnedo G; Oppenheimer F; Arias M; Campistol JM
    Transplantation; 2015 Aug; 99(8):1709-14. PubMed ID: 25675198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.